Resveratrol Attenuates Doxorubicin-Induced Cardiomyocyte Apoptosis in Lymphoma Nude Mice by Heme Oxygenase-1 Induction
- 518 Downloads
Doxorubicin (DOX) has been used in a variety of human malignancies for decades, in particular of lymphoma. But increased cardiomyocyte apoptosis has been implicated in its cardiotoxicity. Resveratrol (RES) generates cardiovascular protective effects by heme oxygenase-1(HO-1)-mediated mechanism. The present study was designed to determine whether RES protected cardiomyocyte against apoptosis through induction of HO-1 in lymphoma nude mouse in vivo. After being developed into lymphoma model, 40 male Balb/c nude mice were randomized to one of the following four treatments (10 mice per group): control, DOX, DOX + RES and DOX + RES + HO-1 inhibitor (zinc protoporphyrin IX, ZnPP). The results showed that DOX injection markedly decreased the body weight, the heart weight and the ratio of heart weight to body weight, but inversely increased cardiomyocyte apoptosis and the level of serum lactate dehydrogenase and creatine kinase. Moreover, DOX injection attenuated HO-1 expression and enzymatic activity as well as increased P53 expression, modulated Bcl-2/Bax expression and enhanced caspase 3 activity. These cardiotoxic effects of DOX were ameliorated by its combination with RES. However, the protective effects of RES were reversed by the addition of ZnPP. Taken together, it is concluded that HO-1 plays a core role for protective action of RES in DOX-induced cardiomyocyte apoptosis in lymphoma nude mice.
KeywordsResveratrol Doxorubicin Cardiotoxicity Apoptosis Heme oxygenase-1
This study was supported by grant 2008Y052 from Youth foundation of Shanghai Municipal Health Bureau (Shanghai, China).
Conflict of interest
The authors have no financial and/or personal relationships with other people or organization that could influence this report.
- 10.Kim, J. W., Lim, S. C., Lee, M. Y., Lee, J. W., Oh, W. K., Kim, S. K., et al. (2010). Inhibition of neointimal formation by trans-resveratrol: Role of phosphatidyl inositol 3-kinase-dependent Nrf2 activation in heme oxygenase-1 induction. Molecular Nutrition & Food Research, 54, 1497–1505.CrossRefGoogle Scholar
- 13.Lopes de Menezes, D. E., Denis-Mize, K., Tang, Y., Ye, H., Kunich, J. C., Garrett, E. N., et al. (2007). Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. Journal of Immunotherapy, 30, 64–74.PubMedCrossRefGoogle Scholar
- 15.Li, S. Y., Gomelsky, M., Duan, J., Zhang, Z., Gomelsky, L., Zhang, X., et al. (2004). Overexpression of aldehyde dehydrogenase-2 (ALDH2) transgene prevents acetaldehyde-induced cell injury in human umbilical vein endothelial cells: role of ERK and p38 mitogen-activated protein kinase. The Journal of Biological Chemistry, 279, 11244–112452.PubMedCrossRefGoogle Scholar
- 17.Childs, A. C., Phaneuf, S. L., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis as well as increased mitochondrial efficiency, superoxid dismutase activity, and Bcl-2:Bax ratio. Cancer Research, 62, 4592–4598.PubMedGoogle Scholar